News
-
Learn how to take control of your Parkinson’s Disease or Essential Tremor!
-
Avion Pharmaceuticals Announces the FDA Approval and Availability of DHIVY™
(February 15, 2022) – Avion Pharmaceuticals, LLC, an Alora Pharmaceuticals company, announced the commercial launch of DHIVY, the first and only carbidopa/levodopa (CD/LD) fractional tablet designed to be easily divided and individualized. Avion gained …
-
LSVT Announces Aware in Care Information Session: Helping individuals with Parkinson’s disease stay safe while in the hospital
(January 19, 2022) – Nearly one-third of people with Parkinson’s disease (PD) in the United States will have a hospital encounter every year. The Parkinson’s Foundation Hospital Care Initiative aims to ensure that all people with PD are “Aware in Care. …
-
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
(January 4, 2022) – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced positive topline results from their pivotal Phase 3 RISE-PD clinical trial evaluating the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluct …
-
Your Voice is Needed. Join Google and LSVT in Project Euphonia.
What: Google is working to make speech recognition more accessible to people with speech disorders. To do this they need samples of disordered speech to train the system. LSVT Global is recruiting people with speech disorders to help. Upon completion o …
-
Supernus bolsters Parkinson’s portfolio with $400 million deal for Adamas Pharma
(October 11, 2021) – Supernus Pharmaceuticals Inc (SUPN.O) said on Monday it would buy Adamas Pharmaceuticals Inc (ADMS.O) for roughly $400 million. The purchase expands Supernus’ roster of treatments for Parkinson’s disease and reduces reliance on its …
-
Amneal Announces Positive Topline Results from Pivotal Phase 3 RISE-PD Clinical Trial of IPX-203 in Patients with Parkinson’s Disease Who Experience Motor Fluctuations
(August 25, 2021) – Amneal Pharmaceuticals, Inc. (NYSE: AMRX) announced positive results from the Phase 3 RISE-PD clinical trial that evaluated the novel formulation, IPX-203, in patients with Parkinson’s disease (PD) who have motor fluctuations. The t …
-
FDA Approves First-of-its-Kind SenSight™ Directional Lead System for DBS Therapy
(June 7, 2021) – Medtronic announced receipt of U.S. Food and Drug Administration (FDA) approval and first U.S. implants of the SenSight™ Directional Lead System for Deep Brain Stimulation (DBS) therapy. SenSight™ allows physicians to deliver precise, …
-
Adamas Completes Acquisition of OSMOLEX ER®
(January 5, 2021) – Adamas completed acquisition of OSMOLEX ER® via a settlement of patent litigation with Osmotica Pharmeceuticals US LLC. OSMOLEX ER® is an FDA-approved, extended-release tablet for the treatment of Parkinson’s disease. Click here to …
-
LSVT Global Offers Tips for Navigating Masks and Parkinson’s Disease
(September 8, 2020) – LSVT Global recently published tips that may improve communication for a person with Parkinson’s disease. To help through the extra challenges communicating while wearing a mask, learn more on LSVT’s website.